Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Free Cash Flow (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Free Cash Flow for 3 consecutive years, with -$33.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 3.58% to -$33.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$143.4 million, a 31.53% increase, with the full-year FY2024 number at -$197.0 million, down 1.64% from a year prior.
  • Free Cash Flow was -$33.8 million for Q3 2025 at Inhibrx Biosciences, down from -$29.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$29.9 million in Q2 2025 to a low of -$64.2 million in Q1 2024.
  • A 3-year average of -$45.3 million and a median of -$43.7 million in 2024 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 46.97% in 2025; the steepest drop was 3.58% in 2025.
  • Inhibrx Biosciences' Free Cash Flow stood at -$56.2 million in 2023, then grew by 22.16% to -$43.7 million in 2024, then rose by 22.66% to -$33.8 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Free Cash Flow are -$33.8 million (Q3 2025), -$29.9 million (Q2 2025), and -$35.9 million (Q1 2025).